The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.
The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally. The initial plasma half-life of pamidronate was short (42 +/- 27 min) and the apparent total plasma clearance was high (471 +/- 298 ml/min). The renal clearance (74 +/- 34 ml/min) was similar to the creatinine clearance (66 +/- 19 ml/min). Most of the renal elimination occurred during and immediately post a 4 h infusion of the drug (23.2 +/- 7.9% in 24 h). The non-renal clearance was ascribed to uptake by bone and deep tissue compartments. Little additional drug appeared in the urine after 24 h. The mean bioavailability was estimated using a parallel study design to be 0.3% for a 300 mg oral dose.
Daley-Yates
P T
PT
Department of Pharmacy, University of Manchester, UK.
Dodwell
D J
DJ
Pongchaidecha
M
M
Coleman
R E
RE
Howell
A
A
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary*; D001943:Breast Neoplasms / Q000378:metabolism*; D004164:Diphosphonates / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000652:urine; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D000077268:Pamidronate
D004164:Diphosphonates; D000077268:Pamidronate